EMA/585843/2019

European Medicines Agency decision

P/0363/2019

of 4 November 2019

on the acceptance of a modification of an agreed paediatric investigation plan for lubiprostone (AMITIZA), (EMEA-000245-PIP01-08-M06) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0363/2019

of 4 November 2019

on the acceptance of a modification of an agreed paediatric investigation plan for lubiprostone (AMITIZA), (EMEA-000245-PIP01-08-M06) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/84/2011 issued on 8 April 2011, the decision P/0190/2012 issued on 24 August 2012, the decision P/0142/2014 issued on 13 June 2014, the decision P/0241/2016 issued on 9 September 2016, the decision P/0353/2017 issued on 1 December 2017 and the decision P/0175/2018 issued on 15 June 2018,

Having regard to the application submitted by Sucampo AG on 26 June 2019 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 18 October 2019, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the waiver.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for lubiprostone (AMITIZA), capsule, soft, oral use, including changes to the waiver, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Sucampo AG, Baarerstrasse 75, 6300 – Zug, Switzerland.

EMA/PDCO/410735/2019
Amsterdam, 18 October 2019

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000245-PIP01-08-M06

Scope of the application

Active substance(s):

Lubiprostone

Invented name:

AMITIZA

Condition(s):

Treatment of constipation

Pharmaceutical form(s):

Capsule, soft

Authorised indication(s):

See Annex II

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Sucampo AG

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Sucampo AG submitted to the European Medicines Agency on 26 June 2019 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/84/2011 issued on 8 April 2011, the decision P/0190/2012 issued on 24 August 2012, the decision P/0142/2014 issued on 13 June 2014, the decision P/0241/2016 issued on 9 September 2016, the decision P/0353/2017 issued on 1 December 2017 and the decision P/0175/2018 issued on 15 June 2018.

The application for modification proposed changes to the agreed paediatric investigation plan and to the waiver.

The procedure started on 20 August 2019.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified. A waiver has been extended to cover a new paediatric subset.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion;
   - to agree to changes to the waiver in accordance with Article 11(1)(a) of said Regulation, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population, in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of constipation

The waiver applies to:

- the paediatric population from birth to less than 6 months of age;
- capsule, soft, oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset;

  and

- the paediatric population from 6 months to less than 6 years of age;
- capsule, soft, oral use;
- on the grounds that the specific medicinal product is likely to be ineffective.

2. Paediatric Investigation Plan

2.1. Condition

Treatment of constipation

2.1.1. Indication(s) targeted by the PIP

Treatment of functional constipation

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Capsule, soft

2.1.4. Measures

Area	Number of studies	Description
Quality	0	*Study 1: deleted during procedure EMEA-000245-PIP01-08-M06.*
Non-clinical	1	**Study 2** Oral toxicity study in juvenile rat

Clinical	2	**Study 3** Multi-centre, double-blind, placebo-controlled study of lubiprostone to evaluate efficacy, safety and pharmacokinetics in children and adolescents from 6 years to less than 18 years of age with functional constipation. (SAG/0211PFC-1131 (formerly 0211SC-1141)) *Study 4: deleted during procedure EMEA-000245-PIP01-08-M06.* *Study 5: deleted during procedure EMEA-000245-PP01-08-M02.* **Study 7** Multi-centre, long term open-label safety study to assess long term safety, efficacy and pharmacokinetics in children and adolescents 6 years to less than 18 years of age with functional constipation. (SAG/0211PFC-11S1 (formerly 0211SC-1142)). *Study 8: deleted during procedure EMEA-000245-PIP01-08-M06.*
Extrapolation, modelling and simulation studies	0	*Study 6: deleted during procedure EMEA-000245-PP01-08-M03.*
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By May 2017
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the medicinal product

Condition(s) and authorised indication(s) - withdrawn since 2018:

1. Treatment of constipation

Authorised indication(s):

- AMITIZA is indicated for the treatment of chronic idiopathic constipation and associated symptoms in adults, when response to diet and other non-pharmacological measures (e.g., educational measures, physical activity) are inappropriate.

Authorised pharmaceutical form(s)

Capsules, soft

Authorised route(s) of administration

Oral use

Withdrawal of Marketing Authorisation:

The applicant has indicated that EU marketing authorisations for lubiprostone (AMITIZA) have been withdrawn:

"The first EU Marketing Authorisation (MA) for lubiprostone (invented name Amitiza) capsules, soft was granted in the UK in 2012. The UK was then used as Reference Member State in a Mutual Recognition Procedure which resulted in MA approvals in 8 additional Member States. However, all of these Marketing Authorisations were subsequently withdrawn / cancelled by the MA holders for commercial reasons. The last Marketing Authorisation withdrawal was from the UK and was completed 14 December 2018. EU Marketing Authorisations for this product to which this PIP was originally linked do not now exist and there are no plans to seek new ones."